Plasma and intrapulmonary population pharmacokinetics of piperacillin/tazobactam in critically ill patients.

Trial Profile

Plasma and intrapulmonary population pharmacokinetics of piperacillin/tazobactam in critically ill patients.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Piperacillin/tazobactam (Primary)
  • Indications Bacterial infections; Nosocomial pneumonia
  • Focus Pharmacokinetics
  • Acronyms PROPEL
  • Most Recent Events

    • 17 Oct 2013 Accrual to date is 100% according to United Kingdom Clinical Research Network record.
    • 17 Oct 2013 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network record.
    • 17 Jul 2013 Accrual to date is 80% according to United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top